Blueprint Of Services For Lung Cancer by Doyle, Yvonne G.
SOUTH EAST INSTITUTE OF PUBLIC HEALTH
AND UNITED MEDICAL AND DENTAL SCHOOLS OF
& ST. THOMAS'S HOSPITALS
DIRECTORATE OF PUBLIC HEALTH MEDICINE
CANCER PROGRAMMES
BLUEPRINT OF SERVICES FOR LUNG CANCER
Prepared by :
Or. Yvonne Doyle.





TYPICAL PATTERNS OF TREATMENT
MODELS OF GOOD PRACTICE
BACKGROUND INFORMATION ON










BLUEPRINT FOR LUNG CANCER INTERVENTIONS AND SERVICES
INTRODUCTION.
Primary lung cancer is the commonest malignant disease in the developed world, and is the
most prevalent form of cancer among men over 65 years. It continues to rise in those aged
over 75 years. Mortality from lung cancer is increasing in women. The condition still has a
short clinical course and a poor prognosis. The literature is in agreement about the effectivness
of preventing lung cancer incidence by targeting smoking behaviour, particularly in preventing
young people taking up smoking. There is further consensus about the lack of a population
screening method which can be recommended, and the desirability of detecting non-small cell
lung cancer early enough for surgical intervention. The effectiveness of treatment for advanced
disease is less marked, and it is of concern that many people who present with lung cancer are
unsuitable for surgical intervention. The role of palliative care is critical in this condition and
this care should be introduced early in the interaction between the patient and the services.
This document is presented in three sections:
I. A summary of interventions available with a classification of effectivness, and a flow
chart of the progress of patients with this condition through the health services
11. Models of good practice in health services drawn from national and international
guidance on the topic
Ill. Supporting information on the interventions available with references.
The classification of the evidence is drawn from the model used by the Canadian Task Force
on Periodic Health Examinations. I
Quality of evidence Strength of reconnnendations
I- Evidence from at least one properly A- There is good evidence to support the
randomised controlled trial recommendation/intervention
Il-Evidence obtained from well designed B- There is fair evidence to support the
trials without randomisation, or with recommendation
confounding factors not adequately
accounted for
Ill-Evidence obtained from well designed C- There is poor evidence to support the
epidemiological studies recommendation
IV-Evidence from comparisons, D- There is fair evidence to exclude this
observational studies or opinions of intervention from practice
respected authorities
E- There is good evidence to exclude this
intervention from practice
'Canadian Task Force on Periodic Health Examinations. Community Medicine Society
Journal 1979;121:1193-1254.
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1. SUMMARY OF INTERVENTIONS
INTERVENTION LEVEL OF RECOMMENDATION
STRENGTH QUALITY
PREVENTION
iv. Smoking cessation programmes: reduction in starting smoking
Provision of health education materials for children is potentially highly effective initially B II
Provision of advice via the mass media are potentially highly effective B II
Community campaigns to reduce smoking(all ages) are potentially effective B II
v. Smoking cessation prograonnes: support for quitting
Advice from GP/primary care team leads to quitting smoking in a proportion of their patients B II
Workplace smoking policies with support is moderately effective in reducing risk B I
Advice from a nurse in antenatal clinic is moderately effective in reducing risk C II
Nicotine chewing gum is moderately effective in reducing risk C/B I
Provision of group support leads to risk reduction in a small proportion of participants C II
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Reduction of exposure to tobacco from passive smoking protects against lung cancer A II
Reduction in air pollution exposure(coal and tar fumes; nickel, zinc, benzpyrene) will not in itself reduce C III/N
incidence
vii. Reduced risk of lung cancer follows reduction in occupational exposure to;
Asbestos A II
Radioactivity B III
Metal workers B III
Arsenicals B III
Inorganic lead B III
viu. Dietary factors
Increase intake of b-carotene containing foods B/C III
IX. Chemoprevention
Compounds with tumour preventive properties are promising but still experimental C ?
x. Identification by genetic markers of at-risk groups is still experimental C ?
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INTERVENTIO LEVEL OF RECOMMENDATION
STRENGTH QUALITY
EARLY DETECTION
Xl. Screening by sputum cytological examination is not recommened at population level E I
xii. Screening by chest radiography is not recommended at population level D I
DIAGNOSIS
Xlll. Diagnostic procedures available include:
(I )Fibreoptic bronchoscopy and TNM staging ofthe tumour A IIIIII
(2)Routine lung function tests A III
(3)CT scanning of the chest and upper abdomen B I
(4)Liver function tests B II
(5)Mediatinoscopy B II
(6)Thoracotomy B II
(7)MRI scanning of the chest and upper abdomen B/C I
(8)Bone scanning and skeletal radiology C II
(9)Bone marrow aspiration C/B II
(lO)CT scanning of the brain and other sitesre.g. adrenal glands) C/B II
(11)Tomography of the chest D II
(l2)Genetic diagnosis with flow cytometry E ?
A diagnosis of lung cancer requires (1 - 2) preferably enhanced by (3-4).
(5) is considered important in patients selected for surgery, and (6) should only be undertaken if
necessary after (1-5) have failed to defme the staging adequately.
(7) is not recommended over (3).
(8-10) are additional tests which can be useful in selected patients if used as a 'road map'





XIV. Non-Small Cell Lung Cancers(NSCLC): early disease-Stage I and II)
LEVEL OF RECOMMENDATION
QUALITY
Surgery(lobectomy the minimal procedure) provides the best chance of cure. Highly dependent on patient
selection.
Pre-operative radiotherapy not recommended
Adjuvant radiotherapy following curative surgery may reduce local recurrence rate; no proven survival
benefit
Pre-operative chemotherapy may reduce the recurrence rate, no unequivocally proven survival benefit
Adjuvant chemotherapy following surgery not standard therapy, but may reduce distant recurrence; survival
data inconclusive.
Photodynamic therapy in tumours of < lcm provides promising results. Use is experimental.












Radiotherapy alone has a modest one-year survival of 40 %; 20 % @ 2 years and 5 %at five years I A
Single agent chemotherapies show low response rates and no survival advantage. I D
Combination chemotherapy, including mitomycin, cisplatin, ifosamide , paclitaxel and vinca alkaloids prolong I A/B
survival as compared with no care, but the value of chcmtherapy is still questioned in advanced disease, and
should only be used in clinical trials
B
Combination chernthcrapy and radiotherapy has been shown to have a potential benefit of 2-7 % .
I
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TREATMENT
XVI. Small Cell Lung Cancer(SCLC).
Combination chemotherapy including combinations of cyclophosphamide, etoposide, methotrexate, I A
nitrosuears, vinca alkaloids, cisplatin aud anthracyclines have led to improved outcomes in trials
The emphasis is on more intense but smaller numbers of doses.
Autologous bone marrow transplant is not of proven survival benefit as a support therapy to more intense I CID
chemotherapy regimens.
Combination chemo and radiotherapy have been shown to have a reduction in relative mortality of 14% over I A
chemotherapy alone. This translates into a 5 %benefit in survival at 3 years.
The place of radical radiotherapy in the long term outcome of SCLC is unclear. It is most effective in local I B
disease and recurrence of local disease.






(I)Prophylactic cranial irradiation: of limited value, toxic, and of no proven benefit in survival
(2)Colony stimulating factors: still experimental
(3)Somatostatin and analogues: role has still to be established
(4)lmmunotherapy(BCG, levirnasole, C parvum): not of proven benefit
(5) Fast neutron therapy: toxic, conflicting results, but not of superior benefit to current therapies
(6)Transfer factor
















XIX. Palliative radiotherapy for patients with loco-regional disease in NSCLC relieves troublesome A I
obstructive symptoms. There is no survival benefit in active treatment unless symptoms are present
xx. Palliative chemotherapy in NSCLC is associated with toxicity and it's value is questionable. CID I
xxi. Clincial evideuce of brain and painful bone metastases in SCLC are alleviated by radiotherapy B II
XXlI. Popnlation based terminal care is required @ 1-2 home care nurses per 250,000 population, B III&IV
particularly those patients with severe pain
XXlll. Specialist palliative services should be available locally to support hospital, hospice, home and B III&IV
primary health care services
xxiv. 12.5 hospital beds per 250,000 population is recommended for patients with specific inpatient needs B IV
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TYPICAL PATTERNS OF TREATMENT FOR LUNG CANCER
The numbers are estimates of the expected numbers in a popnlation of 700,000 (figures in parentheses are percentages of total cases).
679 males




248 (maximum) suitable for surgery
(30%)
Mortality of 5 % for pneumonectomy and
2 % for lobectomy. Persons over 70 years
tolerate surgery poorly.
50 % survival @ Stage 1 at 5 years
40 % survival @ stage II at 5 years
Overall, histological types vary.
Likelihood of snrvival @ 5 years
from 37% to 27%
579 (70%) not suitable for surgery:
Palliative radiotherapy
Combination chemotherapy (intial response of up to 60%);
effects on survival unproven
Specialist palliative services with median survival of 8.5 months
294 females
( 30 % of total cases)
146 SCLC
(15%)
48 with limited disease
(33 %)
Chemotherapy, 7 (15%) alive at 2 years if
limited disease
Combination chemo-and radiotherapy has
indicated 3 year survival of 2(5 %)
98(66%) with extensive disease
Chemotherapy for 49(50%), witb combination
chemo-and radiotherapy for 29(30 %).
Specialist palliative services with median survival of 9 months
Survival of 5 months without treatment
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MODELS OF GOOD PRACTICE
The following documents provided guidance for the principles of good practice, with a special emphasis on purchasing,
Standing Medical Advisory Committee, The Managementof Lung Cancer: Current Clinical Practices. London: HMSO, 1994.
Sanderson H, Mountney L, Harris J. Cancer of the Lung. In: Epidemiologically Based Needs Assessment, Vol1. Oxfrod University Press, 1994.,
Saunders C. Hospice and Palliative Care. An interdisciplinary approach. London: Edward Arnold, 1990.
Worldng Group ofthe Faculty ofClinical Oncology and the Royal College ofRadiologists. Cancer Care and Treatment Services: Advice for Purchasers and Providers. RCR, 1991.
Department of Health and the Welsh Office. A Policy Frameworkfor Commissioning Cancer Services. London: Department of Health, 1995.
The Association of Cancer Physicians. Review of the Pattern of Cancer Services in England and Wales. London: ACP, 1994.
The Royal Marsden NHS Trust. Purchasing and Providing Cancer Services: A Guide to Good Practice.
Younger T. Lung Cancer: Profile of the Evidence. South Thames Regional Health Authority, 1995.
DESCRIPTION
Specific Guidelines for Lung Cancer
1. The most effective way of reducing the incidence of lung cancer is through methods of preventing tobacco smoking, targeted at the young.
2. The aim of clinical management of lung cancer is to achieve a good quality life for the patient for as long as possible. This includes services which provide good
symptom control andpalliative care. Too often, effective care is measured in terms of survival or rumour response to the exclusion of quality of life.
3. Lung cancer demands the closest integration of health and social care. The role of the general practitioner and the primary care team is important at all stages of the
disease.
4. Early detection of symptoms by general practitioners, and speedy referral, ideally within one week contributes to the clinical management of the disease.
5. There should be pre-referral access by general practitioners to X-ray services, and access to specialist and experienced medical staff for the diagnosis and subsequent
management of the disease.
6. A report on the X-ray results should be available to the GP within one week. An outpatient appointment to a specialist within two weeks should be regarded as





7. The appropriate specialists are usually a chest physician, oncologist and thoracic surgeon, with access to radiotherapy services. There should be evidence of collaborative
care between these specialists, and clear locally agreed guidelines identifying which group of doctors have major clinical responsibility at different stages of care.
8. All principal clinical support services should be available on site including expert histopathology services.
9. Doctors and nurses working in priniary care should be kept promptly up to date with the patient's progress, and joint educational activities for general practitioners,
hospital doctors and nurses should be developed locally.
10. Patients and their carers/fainilies should be told of the diagnosis early on, with adequate information about the consequences of the disease, and it's management.
11. If preliniinary investigations suggest that a patient is potentially curable by surgery, he or she should be referred to a thoracic surgeon. There is evidence that
considerably more cases may be suitable for such treatment.
12. There should be co-ordinated nursing services for patients with lung cancer, with care supervised and provided by the appropriate clinical nurse specialist.
13. Clinical trials are of importance in lung cancer management andwherever possible patients who wish to consider active treatment at later stages of the condition should
be referred to a specialist actively engaged in such trials. Data should also be regularly collected for clinical audit.
14. Palliative care should include patient rated quality of life assessments. Good symptom control is integral to lung cancer management and should aini for psychological,
physical and functional well being.
15. Good communication, adequacy of information and continuity of care are all essential components of clinical practice in this condition.
16. Thereare opportunities to improve the organisation andco-ordination of services within andacross sectors. Activity, costs and outcomes need to be assessed more
accurately through audit, review and evaluation.





I. SMOKING CESSATION PROGRAMMES
Health education materials for children produce initially good results but these are hard to sustain. The B 11 1,2
impact is high, as many children receive the messages. The HEA has shown that mass media 1,3
materials can lead to a quitting rate of 5 % at one year; other series have shown quitting rates of up to
I1 %.
Community campaigns are potentially highly effective, leading to quitting rates of up to 15%. B 11 1,4
Advice from the GP and primary care team is known to lead to 5 % quitting rates, although the B 11 1,5
optimal circumstances have to prevail with the service provider and the patient.
Workplace initiatives have a moderate effect, and progranunes are confmed mainly to larger B 11 1,6
employers
Nicotene chewing gum and advice from nurses are moderately effective, with a limited target C/B I 1,7-9
audience.
Group support has led to 20% quitting rates, but is difficult to sustain C 11 10
11. ENVIRONMENTAL RISK FACTORS
Over 20 epidemiological studies have investigated passive smoking and concluded that there is an A 11 11-13
increased risk in the range of 10-50% of getting lung cancer from exposure. Recent overviews have
raised some doubt about the causal nature.
There is not a causal link established between air pollution and lung cancer and research is needed to C 1IIIIV 14,15





m. OCCUPATIONAL EXPOSURE A II 16-18
Although causing only a small proportion of cancers, the IARC has identified over 200 ageuts as
carcinogenic. In the UK, the majority of cases relate to asbestos and lung cancer. B II 19
A recent meta-analysis has found an excess risk of several cancers including lung, in people exposed
to inorganic lead, but the studies have not taken account of confounding factors.
N. DIETARY INFLUENCES BIC III 20-4
The risk of lung cancer is 2.0 times higher among smokers who eat foods low in b-carotene than
among those who eat foods high in b-carotene. There is fair evidence to support an increase in b- C III




The administration of agents to block or reverse carcinogenesis is being investigated in ongoing trials.
The National Cancer Institute in the USA has funded research on 14 compounds that may inhibit
tumour development. This is still at an experimental stage. C .) 27
VI. IDENTIFICATION BY GENETIC MARKERS OF AT-RISK GROUPS
Research on dominant oncogens and tumour supressor genes is stillunder way withprospective
studies. These imtiatives are still at the experimental stage
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INTERVENTION LEVEL OF RECOMMENDAnON
STRENGTH QUALITY REFERENCES
VII. EARLY DETECTION
Frequent cytologic examination of the sputum does not significantly change detection and mortality E I 22,28-30
rates. There is good evidence to exclude from periodic health examinations of asymptomatic people.
Frequent screening by chest readiographhy improves detection rates, but not mortality. There is fair D I
evidence to exclude from periodic examinations
VIII. DIAGNOSIS
Flexible fibreoptic bronchoscopy has become the single most useful diagnostic procedure in the A IVIII 31-32
diagnosis of endobronchial lung carcinoma. The additional procedure of transbronchial needle
aspiration has been found to be valid for diagnosing malignancy in the mediastinum and
micrometastases.
Several prospective trials have shown the sensitivity and specificity of CT scanning over MRI as a all- B I 33,34-36
round tool for imaging thoracic abnormalities. Both modalities are least accurate when detecting
mediastinal lymph nodes.
Mediastinoscopy will improve the diagnostic yield, but should be used in selected circumstances of B 11 37-38
diagnostic difficulty, after redaiological procedures have been undertaken. Thoracotomy can B 11
complement mediastinoscopy but has a defmite mortality and morbidity.
Routine assessments of distant metastases, particularly if asymptomatic remains controversial. C 11 31,34,39
Standard tomography has a limited place in assessment and diagnosis. D 11 40
The contribution of flow-cytornetry in evaluation of lung cancer remains disputable. DIE ? 41
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INTERVENTION LEVEL OF RECOMMENDATION
STRENGTH QUALITY REFERENCES
IX. TREATMENT
NON-SMALL CElL LUNG CANCERS
The five year survival rate for those suitable for surgery is reported as 50-70 %. Less than30 % of A II 1,31,32,42
newly diagnosed cases are suitable for surgery. Tumour stage is more important than histology.
Randomised controlled trials have not yet been completed to prove the benefit conclusively. There is
some evidence that more people could benefit from surgery than currently receive it. The North
American Lung Cancer Study Group has initiated a prospective randomised trial of limited resection
V lobectomy . At 2 years, there was a significant increase in local recurrence in the limited resection A I 43
group. Lobectomy is the minimal procedure recommended.
There is no place for pre-operative radiotherapy outside of clinical trials,as there is No demonstrable E I 44
survival benefit
Pre-operative chemotherapy has been the focus of Phase II trials recently. Studies are flawed by the CID I 45
lack of an adequate control group. Toxicity rates are significant andsurvivaldata are inconclusive
Two randomised controlled trials have found a significant decrease in distant metastases from surgery C/B II 46-8
and sequential combination chemotherapy(CAP regimen), but other trial data are inconclusive, and
this treatment is not yet considered standard.
Phase I & II trials in Japan indicate that for cancers < lcm complete eradication can be achieved in C '! 49
90 % of cases using photodynamic therapy; it is considered a promising curative treatment for early
NSCLC. It also enhances responses to radiotherapy
16
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In late disease, a meta-analysis of 11 RCTs has shown that thoracic irradiation in patients receiving chemotherapy I A
for local disease led to an odds of surviving at 2 years of 1.5 over those receiving no radiotherapy. This was
associated with treatment related deaths. Seven randomised trial' of combination chemotherapy following radiation
and best supportive care showed similar results. Trials of concurrent chemo and radiotherapy have led to conflicting
results.
Meta-analyses have shown that combination chemotherapy, especially with newer agents result in an odds ratio of I A/B
death of 0.44 as compared with supportive treatment in late disease. Toxicity is considerable. The National Cancer
Institute of Canada has indicated that at least some chemotherapy regimens may be less costly than best supportive
care
There is continued debate about the role of radiotherapy alone in advanced disease, and clinical trials are ueeded to I C
determine its benefit to survival. It has been shown in observational studies to have significant palliative benefits in
local obstruction
SMALL CELL LUNG CANCER
Administration of three or four drugs is required for optimal results in combination chemotherapy, leading to a 60- I A
90 % initial response. TIns, combined with intensified treatment periods have led to treatment related deaths.
Hematopoietic growth factors have been disappointing in reducing these deaths. aod RCTs are recommended to I CID
examine the benefits of this adjuvant treatment.













INTERVENTIONS LEVEL OF RECOMMEDNATION REFERENCES
STRENGTH QUALITY
TREATMENT
OTHER FORMS OF TREATMENT FOR NSCLC AND SCLC
Prophlyactic cranial irradiation(PCI) may influence long term survival of patientswith limited stage C I 64-6
disease, but this is not clearly established. Ten randomised controlled trials have examined the value of
PCI and have found no demonstrable survival benefit, although brain recurrences can be reduced,
This treatment is not recommended as standard.
Granulocyte macrophage colony stimulating fact has been shown to induced increased production of C ? 67
blood cells, which may reduce toxicity of chemotherapy. This treatment is still experimental
Somatostatin and analogues inhibit release of various hormones and may inhibit tumour growth. It is a C ? 68
promising adjuvant therapy in cancer, but as yet of unproven benefit
Trials have shown a slight improvement in disease -free survival for patients treated with C II 69-70
immunotherapy, but the trial data are not detailed enought to permit meta-analysis. There is insufficient
evidence to justify the use of these treatments.
Twenty five RCTs have examined the benefits of fast neutron therapy. None has demonstrated CID I 71-2.
neutrons to be advantageous over photons, nor that the treatment is safe. The National Cancer Institute
of the USA has sponsored RCTs which show that in selected patients with inoperable NSCLC, fast
neutron therapy may provide therapeutic benefit, but at the cost of severe toxicity.
RCTs on transfer factor show conflicting results, and several show no clmical benefit. D II 73
Studies using tracheobronchial stents have found them useful in high grade stenosis. Mean duration of B III 74
stenting was 3.35 months in one study(longest 2.7 years).
Despite much literature, the treatment of pulmonary metastases remains controversial C II 75-6
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INTERVENTION LEVEL OF RECOMMENDATION REFERENCES
STRENGTH QUALITY
AFTERCARE
Results horn the MRC trial of palliative radiotherapy suggest that smaller fractions are as effective iu A I 1,77
controlliug symptoms as larger ones.
Chemotherapy may prolong survival iu advanced disease in SCLC for several months, but will lead CID I 78-80
only to a small reduction iu relapse rate. Its role is questioned iu advanced NSCLC.
Population based termiual care and specialist palliative services should be available to support people B IV 1, 81-2
iu home, hospice, hospital and primary care settiugs
19
References
1. Sanderson H, Mountney L, Harris 1. Cancer of the Lung. Epidemiologically Based Needs Assessment. London: NHS Management Executive, 1994.
2. Goddard E. Smoking among secondary school children in England in1988. London: HMSO, 1989.
3. Egger G, Fitzgerlad W, Frape G et al. Results of large scale media anti-smoking campaign in Australia. BMJ 1983;287: 1125-8.
4. Wilson DH. Evaluation of the South Australian pilot stop smoking progranuue in Whyalla, Port Augusta and Port Pirie, March 1983. South Australia Health Commission, 1984.
5. Russell MAH, Wilson C, Taylor C, Baker CD. Effect of general practitioners advice against smoking. BMJ 1979;2:231-5.
6. Fisher KJ, Glascow RE, Terborg JR. Work site smoking cessation: a meta-analysis of long term quit rates from controlled studies. J ace Medicine 1990;32:429-39.
7. Windsor RA, Warner KE, Cutter GR. A cost effectiveness analysis of self-help smoking cessation methods for pregnant womeu. Public Health Reports 1988;103:83-8.
8. Mullen PD, Quinn YP, Ershoff DH. Maintenance of non-smoking postpartum by women who stopped smoking during pregnancy. Am J Public Health 1990;80:992-4.
9.Marshall A, Raw M. Nicotene chewing gum in general practice: effect offollow-up appointtnents. BMJ 19R5;290:1397-8.
10.Raw M. The treattnent of cigarette dependence. In: Israel Y, Galser FB, Kalant H, Popham RE, Sclunidt W, Smart RG (eds). Research advances in Alcohol and Drug problems.
Yol4 . New York: Plenum Publishing Coorporation, 1978: p 441-85.
II.Gross AJ. Presentation: The risk of lung cancer in nonsmokers in the United States and its reported association with environmental tobacco smoke. J Clin Epidemiology
1995;48:587-98.
12.Preventive Medicine. A report of a working party of the Royal College of Physicians. London: RCP Publications, 1991.
13.Wald NJ, Nanchatal K, Cuckle H. Does breathing other people's smoke cause lung cancer? BMJ 1983; 293: 1217.
14. Association of London Authorities, London Boroughs Association and the South East Institute of Public Health. Air Quality in London 1994. Tunbridge Wells: The South East
Institute of Public Health, 1995.
15. Dockery DW et al. An association between air polluation and mortality in six US cities. Nengl J Med 1993;329:1753-9.
20
References cont/d....
16. Souharni R, Tobias J. Cancer and its management. Edinburgh: Blackwell Scientific Publications, 1995. p 227-249.
17.Intemational Agency for Researcb on Cancer. Evaluation of carcinogenic risks to humans. IARC monographs, Suppl 7. Lyon: IARC, 1987.
18. Doll R, Peto R. The causes of cancer. Oxford: Oxford University Press, 1981.
19. Fu H, Boffetta P. Cancer and occupational exposure to inorganic lead compounds: a meta-analyais of published data. Occupational and Environmental Medicine 1995;52:73-81.
20. Man T. Solid tumours- chemoprevention with retinoids. Leukaemia 1994;8:1785-90.
21.Willet WC. Vitamin A and lung cancer. Nutrition Reviews 1990;48:201-11.
22. Anonymous. Periodic health exanrniation, 1990 update: 3. Interventions to prevent lung cancer other than smoking cessation. Canadian Task Force on the Periodic Health
Examination. Can Med Ass J 1990;143:269-72.
23.Shekle R, Liu S, Raynore W et al. Dietary vitamin A and risk of cancer in the Western Electric Study. Lancet 1981;2: 1185-90.
24.Paganini-Hill A, Chao A, Poss R et aI: Vitamin A, beta-carotene and the risk of cancer: a prospective study.J Natl Cancer Inst 1987;79:443-8.
25.Benner SE, Lippman SM, Hong WK. Chemoprevention of lung cancer. Chest 1995;107:316S-321S.
26.Castonguay A. Methods and strategies in lung cancer control. Cancer Research 1992;52:2641S-2651S.
27'!ohru;on BE, Kelley MJ. Overview of genetic and molecular events in the pathogenesis of lung cancer. Chest 1993;103: IS-3S.
28. Fontana RS, Sanderson DR, Woolner LB et al. Screening for lung cancer. A critique of the Mayo Lung Project. Cancer 1991;67: 1155-64.
29.Strauss GM, Gleason RE, Sugarbaker DJ. Chest Xray screening improves outcome in lung cancer. A reapproisal of randomised trials on lung cancer screening. Chest
1995; 107:270S-279S.
30. Epler GR. Screening for lung cancer. Is it worthwhile? Postgraduate Medicine 1990;87: 181-6.
3 1.Lyubsky S, Jacobson MJ. Lung Cancer. Making the diagnosis. Chest 1991;100:511-20.
21
References cont/d ...
32.Standing Medical Advisory Conninttee convened by the Chief Medical Officer. Management of Lung Cancer: Current Clinical Guidelines. London: Department of Health,
1994.
33.Fontana RS. Meta-analysis of computed tomography for staging non-small cell lung cancer. Am Rev Res Dis 1990;141:1093-4.
34.Patterson GA. Lung Cancer Staging. Chest 1991;100:520-22.
35. Pugtach RD. Radiologic evaluation in chest malignancies. A review of imaging modalities. Chest 1995;I07:294S-297S.
36. Shepherd FA. Screening, diagnosis, and staging of lung cancer. Current Opinion in Oncology 1993;5:310-22.
37.Pearson FG. Current status of surgical resection for lung cancer. Chest 1994;106:337S-339S.
38.Goldstraw P. Mediastinoscopy vs Thoracotomy. In: Lung Cancer. Frontiers in Science and Treatment. Genoa: Grafica L. P. , 1994.
39.Templeton PA, Caskey Cl, Zerhouni EA. Current uses of CT and MR imaging in the staging of lung cancer. Radiol Clinics of North America 1990;28:631-46.
4O.Webb WR. The role ofmagnetic resonanceimaging in the assessment of patients with lung cancer: a comparison with computed tomography. J Thoracic hnaging 1989;4:65-75.
41.Jeanfaivre T, Chassevent A, Larra F, Tuchais E. Contribution of flow cytometry in the prognostic evaluation of non-small-cell lung cancers. Review of the literature. Bulletin
du Cancer 1994;81:605-9.
42. Inouye SK, Sox He. Standard and computed tomography in the evaluation of neoplasms of the chest. A comparative efficacy assessment. Annals of Internal Medicine 1986;
105:906-24.
43.Ginsberg RJ. Extent of resectionin non-smallcell lung cancer; Is lobectomy required? The role of limited resection. In: Lung Cancer. Frontiers in Science and Treaunent. Genoa:
Grafica L. P. , 1994.
44.Lederle FA, Niewoehner DE. Lung cancer surgery. A critical review of the evidence. Arch Int Med 1994;154:2397-400.
45.Payne DG. Is preoperative radiation therapy indicated in non-small cell cancer of the lung? Lung Cancer 1994;10 Suppl I: S205-12.
46.Holmes EC, Ruckdeschel JC. Preoperative chemotherapy for locally advanced non-small cell lung cancer. Seminars in Oncology 1994;21:97-100.
47. Green MR. Does adjnvant chemotherapy decrease distant metastasis formation in patients with non-small cell lung cancer" Lnng Cancer 1994;1OSuppl I: S187-94.
22
References cont/d..
48. Crump M. Postoperative chemotherapy for resected non-small cell lung cancer. World J Surgery 1993; 17:735-40.
49.Lam S. Photodynamic therapy oflung cancer. Seminar in Oncology 1994;21:15-6.
50.Warde P. Payne D. Does thoracic irradiation improve survival and local control in limited stage small cell carcinoma of the lung'! A meta-analysis. J Clin Oncol 1992;10:890-95.
51.Murren JR, Buzaid AC. Chemotherapy and radiation for the treatment of non-small cell lung cancer. A critical review. Clinics in Cehst Medicine 1993;14:161-71.
52.Negoro S, Fukuoka M. Recent progress in chemotherapy for advanced lung cancer. Gan to Kagaku Ryoho 1995; 22:451-60.
53. Marino P, Pampallona S, Preatoni A, Cantoni A, Invemizzi F. Chemotherapy vs supportive care in advance non-small cell lung cancer. Results of a meta-analysis of the
literature. Chest 1994;106:861-5.
54. Miller VA, Rigas JR, Grant SC, Pisters KM, Kris MG. New chemotherapeutic agents for non-small cell lung cancer. Chest 1995;107: 306S-31S.
55.Evans WK. Management of metastatic non-small cell lung cancer and a consideration of cost. Chest 1993; 103:68S-71S.
56. Darnstrup L, Poulsen HS. Review of the curative role of radiotherapy in the treatment of non-small cell lung cancer. Lung Cancer 1994;11:153-78.
57.Stephem RJ, Girling DJ, Machin D. Treatment related deaths in small cell lung cancer trials: can patients at risk be identified? Medical Research Council Lung Cancer Working
Party. Lung Cancer 1994;11:259-74.
58.Hamen HH, Rorth M. Lung cancer. Cancer chemotherapy and biological response modifiers 1994; 15:484-500.
59. Van Zandwijk N. Are we moving towards continuous treatment in small cell lung cancer'! Anticancer Research 1994;14:309-11.
60.Jett JR. Current treatment of unresectable lung cancer. Mayo Clinic Proceedings 1993;68:603-11.
61. Tiefengraber E, Sebasta C, Keir P, Ruckser R, Habertheuer KH, Hinterberger W. Possible role of autotransplantation in small cell bronchial carcinoma. Wiener Medizinische
Wochenschrift 1995;145:50-2.
62. Kawahara M. Phase ill studies of combined chemotherapy and radiation in locally advanced non-small cell lung cancer and limited small-cell lung cancer. Gan to Kagaku Ryoho
1995;22:335-40.
63. Ihde DC. Small cell lung cancer. State of the art therapy 1994. Chest 1995;107:243S-248S.
23
References cont/d ...
64.Abner A. Prophylactic cranial irradiation in the treatment of small cell carcinoma of the Inng. Chest 1993;103:445S-448S.
65.Jackson DV, Case LD. Small cell lung cancer: a 10 year perspective. Seminars in Oncology 1986;13:63-74.
66. Kristjansen PE. Should current management of small cell lung cancer include prophylactic cranial irradiation? Lung Cancer 1994;10 Suppl I: S319-29.
67. drings P, Fischer JR. Biology and clincial use of GM-CSF in lung cancer. Lung 1990; 168:1059-68.
68.Evers BM, Parekh D, Townsend CM, Thompson JC. Somatostatin and analogues in the treaunent of cancer. A review. Ann Surg 1991;213: 190-8.
69.Fishbein GE. lmmunotherapy of lung cancer. Seminars in Oncology 1993;20:351-8.
References cont/d ...
70.Taghaferri F, Sirovicj I. Stipa F, Valente MG, Pupelis G, Tremiterra S. Systemic specific active innnunotherapy for solid tunours. An overview about cancer vaccinetherapy.
Recenti Pregressi in Medicina 1994;85:591-6.
71. Koh WJ, Griffin TW, Laramore GE, Stelzer KJ, Russell KJ. Fast neutron radiation therapy. Results of phase 11 randomised trials in head, neck, lung and prostate cancers. Acta
Oncologica 1994;33:293-8.
72. Duncan W. An evaluation of the results of neutron therapy trials. Acta Oncologica 1994;33:299-306.
73. Spitler LE, Miller L. Clinical trials of transfer factor in malignancy. Journal of Experimental Pathology 1987;3:549-64.
74. Dumon JF, Venuta F, Kovitz KL, Dumon MC. Tracheobronchial stents: a 5 year experience with the Dumon steraard a review of other current stents. In: Lung Cancer. Frontiers
in Science and Treaunent. Genoa: Grafica LP, 1994:255-64.
75.Todd TR. Pulmonary metastectomy. Current indications for removing lung metastases. Chest 1993; 103:40 1S-403S.
76.Barr LC, Skene AI, Thomas JM. Metastasectomy. British J Surgery 1992;79:1268-74.




78.Rubens RD, Towlson KE, Ramirez Al, Coltart S, Slevin ML, Terrell C, Tirnofby AR. Appropriate chemofberapy for palliating advanced cancer. BMJ 1992;304:35-40.
79.Adelstein DJ. Palliative chemofberapy for non-small cell lung cancer, Seminars in Oncology 1995;22:35-9.
80.Loehrer PJ. Palliative therapy: extensive small cell lung cancer. Seminars in Oncology 1995;22:40-4.
81.Department of Health and the Welsh Office. A Policy Framework for Commissioning Cancer Services. A report by the Expert Advisory Group on Cancer to the Chief Medical
Officers of England and Wales. London; Department of Health, 1995.
82.Standing Medical Advisory Committee/Standing Nursing Advisory Committee. The principles and provision of palliative care. London: Department of Health, 1992.
25
